Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

Slides:

Advertisements

Similar presentations

Cell Physiol Biochem 2017;44:1867– DOI: /

Advertisements

Fig. 1. TP is highly expressed in myeloma.

Fig. 1. Loss of circadian rhythms in iKO mice.

Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

Fig. 5. Blocking LTB4 during initial lymphangiogenesis period abrogates the therapeutic benefit of LTB4 antagonism. Blocking LTB4 during initial lymphangiogenesis.

A FOXO3a-BIM cascade mediates sensitivity to PARP and MEK inhibition

BET inhibition and depletion repress the expression of BRCA1 and RAD51

Fig. 4. Bexarotene promotes PPARδ activation of target genes in mouse brain and muscle. Bexarotene promotes PPARδ activation of target genes in mouse brain.

Fig. 2. Mechanism of PD-L1 down-regulation in NOD HSPCs.

Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.

Fig. 4. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive and HBeAg-negative chimpanzees. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive.

Reduction of Sca-1 increases PPARγ expression.

Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.

Fig. 8. In vivo suppression of MM by CMLD

Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.

Fig. 1 ZIKV-related flaviviruses cause fetal demise in mice that can be prevented by mAb treatment. ZIKV-related flaviviruses cause fetal demise in mice.

Fig. 2. GPC3 expression in normal and tumor tissues.

Expression of CD36 and psap in a TMA of human ovarian cancer patients

Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.

Fig. 4 Expression of cleaved caspase 3, PD-L1, and PD-1 in HGGs after reovirus treatment. Expression of cleaved caspase 3, PD-L1, and PD-1 in HGGs after.

Fig. 3. Wisper controls CF behavior and survival.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Fig. 6. HERV-K activation by TDP-43 and identification of binding sites on LTR. (A and B) Stem cell–derived neurons were transfected with either pcDNA.

Fig. 5. Stimulation of EPO expression and secretion under hypoxic culture conditions. Stimulation of EPO expression and secretion under hypoxic culture.

CHK1 downregulation upon ERG overexpression.

Fig. 1. Generation of the ΔEx50 mouse model.

Microarray analysis of phospho-Twist1–responsive genes.

Fig. 1. Muscles of LAMA2 MD patients and dyW/dyW mice contain high amounts of laminin-α4 and show deficits in BM. Muscles of LAMA2 MD patients and dyW/dyW.

Fig. 5 Hypoxic tumors from obese mice associate with increased production of IL-6 by adipocytes and myeloid cells. Hypoxic tumors from obese mice associate.

Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.

Merlin-deficient RAS-mutant cells and murine PDTCs are more sensitive to MEK inhibition. Merlin-deficient RAS-mutant cells and murine PDTCs are more sensitive.

Fig. 2. Circulating VEGF in GCA patients up-regulates microvascular endothelial Jagged1. Circulating VEGF in GCA patients up-regulates microvascular endothelial.

Fig. 7. KIF11 informs patient prognosis, and targeting improves survival in a preclinical model. KIF11 informs patient prognosis, and targeting improves.

Fig. 4. Genetically engineered PD-L1

Fig. 5 Local gel scaffold for T cell memory response.

Fig. 2 Fas controls IL-1RA–sEV secretion in murine MSCs.

Fig. 1 BX795 suppresses HSV-1 infection.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 1. PGBD5-expressing cells do not tolerate deficiency of nonhomologous end-joining DNA repair. PGBD5-expressing cells do not tolerate deficiency of.

Fig. 5. Nutlin-3 treatment rescues the proliferation and differentiation of NPCs in vitro. Nutlin-3 treatment rescues the proliferation and differentiation.

Fig. 4 TNF-α up-regulates Fas/Fap-1 expression to promote IL-1RA–sEV release in murine MSCs. TNF-α up-regulates Fas/Fap-1 expression to promote IL-1RA–sEV.

Fig. 2 In vitro and preclinical study with 18F-MPG.

CD facilitates RCT in vivo and promotes urinary cholesterol excretion

Selection of a 4-1BB-endodomain–based anti-EGFRvIII CAR construct

Fig. 1 LB100 and LB102 specifically inhibit PP2A phosphatase activity and the growth of BCR-ABL+ cells. LB100 and LB102 specifically inhibit PP2A phosphatase.

Pharmacologic inhibition of eIF5A hypusination sensitizes KRas-driven tumor cells to MEK and KRas inhibition. Pharmacologic inhibition of eIF5A hypusination.

Expression changes of specific epigenetic-controlled tumor-related genes by the prenatal/maternal BSp treatment. qRT-PCR and Western blot analysis were.

eIF5A-PEAK1 signaling regulates KRAS protein expression.

Fig. 2. CD treatment facilitates regression of murine atherosclerosis.

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

Fig. 2 PRC1 activity is required for leukemic cell growth independently of p16 and p19 expression. PRC1 activity is required for leukemic cell growth independently.

Identification of Z-FA-FMK as a potent compound that increases SMN protein expression in HEK293 and patient fibroblast cells. Identification of Z-FA-FMK.

Fig. 5. Mutant KRAS increases HR capacity and MEKi decreases HR capacity in RAS mutant cells, causing increased DNA damage. Mutant KRAS increases HR capacity.

Effects of Z-FA-FMK on SMN protein expression in type II SMA patient fibroblast cells (GM22592). Effects of Z-FA-FMK on SMN protein expression in type.

ONC201 activates the ISR. ONC201 activates the ISR. (A) Western blotting analysis for ATF4, CHOP, ATF3, and TRB3 on lysates from HCT116 cells cultured.

Aβ-mediated Ras-MAPK signaling and Cyclin D1 expression in B103 cells are dependent on APP expression and can be reversed with MEK or Ras inhibition. Aβ-mediated.

CD mediates metabolism and efflux of crystal-derived cholesterol

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

Fig. 1. DEL-1 is expressed by human and mouse osteoclasts.

Fig. 6 RUNX/CBFB interaction inhibitor, Ro5-3335, significantly decreases mouse neurofibroma growth in vivo. RUNX/CBFB interaction inhibitor, Ro5-3335,

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.

Gramicidin A (GA) decreases HIF protein expression in RCC cells.

PD and efficacy of AZD4785 in KRAS mutant lung cancer xenograft models

Fig. 6 Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9 in vivo. Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9.

Fig. 3 Effects of ASO and eGLP1-ASO conjugates on gene expression and protein levels in vitro in cell lines and primary mouse islet cells. Effects of ASO.

Knockdown of ROR1 increases the invasive potential of melanoma cells in vitro and in vivo. Knockdown of ROR1 increases the invasive potential of melanoma.

PD and efficacy of AZD4785 in a KRAS wild-type lung cancer PDX model

Presentation transcript:

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. (A) Sequence and binding region of AZD4785 to the 3′UTR of KRAS mRNA transcript. ds, unmodified bases; ks, cEt-modified bases; mC, 5-methylcytosine; ORF, open reading frame. (B) Relative expression of RAS mRNA isoforms measured by qRT-PCR in A431 cells after 72 hours of treatment with AZD4785 or CTRL ASO. Expression was normalized to ACTIN and shown relative to phosphate-buffered saline (PBS). Representative data from a minimum of two independent experiments are shown. (C) Western blot analysis of RAS and vinculin protein in A431 cells after 72 hours of treatment with CTRL ASO or AZD4785. (D) Mice bearing A431 tumors were treated with PBS or with 16, 32, or 48 mpk of AZD4785 5× weekly for 3 weeks. RAS isoform expression was measured in tumors at the end of the study by qRT-PCR. Expression was normalized to ACTIN and shown relative to PBS. The graph shows individual tumor data, treatment group mean, and SE. mpk/w, mpk/week. (E) IHC analysis of KRAS protein expression in A431 tumors after AZD4785 treatment. Scale bars, 200 μm. Sarah J. Ross et al., Sci Transl Med 2017;9:eaal5253 Published by AAAS